Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MR1-1 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

NCT02084875
View directory record Official record
Conditions
Healthy
Interventions
tofacitinib modified-release (MR) formulation
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 30, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

NCT02236988
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Apremilast Immediate Release, Apremilast Modified Release 1, Apremilast Modified Release 2, Apremilast Modified Release 3, Apremilast Modified Release 4, Apremilast Modified Release 5, Apremilast Modified Release 6, Apremilast Modified Release 8, Apremilast Modified Release 9, Apremilast Modified Release 11, Apremilast Modified Release 12, Apremilast Modified Release 13, Apremilast Modified Release 14
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 30, 2026, 12:09 PM EDT
Terminated Phase 1 Interventional

Study of Immunotoxin, MR1-1

NCT01009866
View directory record Official record
Conditions
Supratentorial Malignant Brain Tumor
Interventions
MR1-1
Biological
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 30, 2026, 12:09 PM EDT